Healthcare Professionals

Arctic Front Advance

Cardiac CryoAblation Catheter

Clinical Studies and Outcomes

  

Expand All

Stop AF

Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) Trial Confirms the Safety and Effectiveness of Arctic Front1

Objective

  • To confirm the safety and effectiveness of the Arctic Front system when used to treat patients with drug refractory Paroxysmal Atrial Fibrillation (PAF)

Methods

  • Patients with drug-refractory paroxysmal atrial fibrillation
  • Failure of 1 or 2 antiarrhythmic drugs (flecainide, propafenone, and sotalol)
  • Total of 245 patients randomized 2:1 to cryoablation or AF medication
  • 26 centers in the United States and Canada
  • Safety and effectiveness follow-up conducted at 12 months
  • Patients followed via weekly and symptom initiated transtelephonic monitoring, periodic electrocardiogram, clinical follow-up at 1, 3, 6, 9 and 12 months and 24-hour Holter at 6 and 12 months


Primary Safety End Points Achieved

Cryoablation Procedure Events*
Defined as a subset of device or procedure- related serious adverse events.

Safety and Effectiveness with Arctic Front Cardiac CryoAblation Catheter

Major AF Events**
Defined as which were serious adverse events related to atrial fibrillation.

Safety and Effectiveness with Arctic Front Cardiac CryoAblation Catheter


Primary Effectiveness End Points Achieved

69.9% achieved treatment success at 12 months

Safety and Effectiveness with Arctic Front Cardiac CryoAblation Catheter


* CPEs were device- or procedure-related serious adverse events (SAE) categorized as access site complications, cardiac damage, pulmonary vein (PV) stenosis, embolic complications, arrhythmias, unresolved phrenic nerve palsy, and death.
** MAFEs were serious adverse events categorized as cardiovascular death, myocardial infarction, stroke, or hospitalization for AF recurrence/ablation, flutter ablation, embolic events, heart failure, hemorrhage or antiarrhythmic drug treatment

 

Reference

1

Medtronic Inc., Arctic Front Cardiac CryoAblation Catheter clinical reports, in support of FDA premarket approval.

Arctic Front Advance Data